Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Femasys's Enterprise Value is $37.39 Mil.
Femasys's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-17.20 Mil. Therefore, Femasys's EV-to-EBIT ratio for today is -2.17.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Femasys's Enterprise Value is $37.39 Mil.
Femasys's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-16.33 Mil. Therefore, Femasys's EV-to-EBITDA ratio for today is -2.29.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Femasys's Enterprise Value is $37.39 Mil.
Femasys's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $1.63 Mil. Therefore, Femasys's EV-to-Revenue ratio for today is 22.95.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Femasys's Enterprise Value is $37.39 Mil.
Femasys's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-20.29 Mil. Therefore, Femasys's EV-to-FCF ratio for today is -1.84.
Femasys Enterprise Value Historical Data
The historical data trend for Femasys's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Femasys's Enterprise Value
For the Medical Instruments & Supplies subindustry, Femasys's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Femasys's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Femasys's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Femasys's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Femasys (NAS:FEMY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Femasys's current Enterprise Value is $37.39 Mil.
Femasys's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.20 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Femasys's current Enterprise Value is $37.39 Mil.
Femasys's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.33 Mil.
Femasys's current Enterprise Value is $37.39 Mil.
Femasys's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.63 Mil.
Femasys's current Enterprise Value is $37.39 Mil.
Femasys's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Femasys Enterprise Value Related Terms
Thank you for viewing the detailed overview of Femasys's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FEMY has been successfully added to your 